Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital, No. 31 of Jinan Road, Dongying, 257034, Shandong, China.
J Orthop Surg Res. 2019 Sep 18;14(1):313. doi: 10.1186/s13018-019-1322-7.
This study aimed to assess the efficacy of water-filtered infrared A (wIRA) in sacroiliitis in male patients with ankylosing spondylitis (AS) and the effect of wIRA therapy on serum vascular endothelial growth factor (VEGF).
One hundred twenty male AS patients with active sacroiliitis were randomly divided into wIRA group and control group. wIRA treatment was performed twice daily for 5 consecutive days with 24-h interval before switching the treatment (crossover design). Bath ankylosing spondylitis disease activity index (BASDAI) scores, pain visual analogue scale (VAS), and morning stiffness VAS were recorded prior to and after each treatment period. Additionally, C-reactive protein (CRP), serum VEGF, and resistance index (RI) of sacroiliac joints detected by ultrasonography were recorded at baseline and after the first and second treatment period, respectively. The efficacy was examined by using repeated measures analysis of variance (ANOVA).
BASDAI, pain VAS, and morning stiffness VAS scores decreased significantly (P < 0.001) after wIRA treatment and no-wIRA treatment (control group), and the difference between the two groups was significant (P < 0.001). CRP declined and RI increased during the wIRA treatment as compared with the no-wIRA treatment (P < 0.001). The increase in RI was associated with improvement of pain VAS scores (P = 0.018), while serum VEGF was unaffected by the treatment.
wIRA treatment achieved symptom and pain relief for AS patients with active sacroiliitis. wIRA treatment also improved RI revealed by ultrasonography, and this effect was associated with improved pain VAS scores.
本研究旨在评估水过滤红外 A（wIRA）在男性强直性脊柱炎（AS）患者中骶髂关节炎的疗效，以及 wIRA 治疗对血清血管内皮生长因子（VEGF）的影响。
将 120 例活动性骶髂关节炎的男性 AS 患者随机分为 wIRA 组和对照组。wIRA 治疗每天进行两次，连续 5 天，两次治疗之间间隔 24 小时（交叉设计）。在每次治疗前后记录浴强直性脊柱炎疾病活动指数（BASDAI）评分、疼痛视觉模拟评分（VAS）和晨僵 VAS。此外，在基线、第一次和第二次治疗后分别记录超声检测的 C 反应蛋白（CRP）、血清 VEGF 和骶髂关节阻力指数（RI）。采用重复测量方差分析（ANOVA）检验疗效。
wIRA 治疗和无 wIRA 治疗（对照组）后，BASDAI、疼痛 VAS 和晨僵 VAS 评分均显著降低（P<0.001），两组间差异有统计学意义（P<0.001）。与无 wIRA 治疗相比，wIRA 治疗期间 CRP 降低，RI 升高（P<0.001）。RI 的增加与疼痛 VAS 评分的改善相关（P=0.018），而血清 VEGF 不受治疗影响。
wIRA 治疗可缓解活动性骶髂关节炎 AS 患者的症状和疼痛。wIRA 治疗还可改善超声显示的 RI，且该效果与疼痛 VAS 评分的改善相关。
